Review Article: An Update on Non‐Invasive Tests for Steatotic Liver Disease ‐ Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies | Synapse
April 8, 2026
Review Article: An Update on Non‐Invasive Tests for Steatotic Liver Disease ‐ Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies
Puntos clave
The aim is to update knowledge on non-invasive tests for diagnosing and managing steatotic liver disease.
Analyzed findings from the ESSENCE Phase 3 Trial
Reviewed longitudinal studies on at-risk MASH
Evaluated pharmacologic treatments including semaglutide
Treatment with semaglutide is recommended for patients with high-risk MASH
Highlights improved outcomes in patients showing severity of liver conditions
Suggests a need for ongoing evaluation of non-invasive testing methods
Resumen
Pharmacologic treatment for MASH, including semaglutide, should be offered to patients with at-risk MASH who are at the highest risk of MALO.